Number needed to treat for time-to-event data with competing risks

Statistics in Medicine

Volumn 33, Issue 2, 2014, Pages 181-192

  Gouskova, Natalia A ^a   Kundu, Suprateek ^a   Imrey, Peter B ^b   Fine, Jason P ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Competing risks; Number needed to treat; Time to event data

Indexed keywords

ARTICLE; BREAST CANCER; CLINICAL TRIAL (TOPIC); COMPETING RISK; CONTROLLED STUDY; CUMULATIVE INCIDENCE FUNCTION; HUMAN; INFERENTIAL STATISTICS; NUMBER NEEDED TO TREAT; RISK; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; TIME TO EVENT DATA;

COMPETING RISKS; NUMBER NEEDED TO TREAT; TIME-TO-EVENT DATA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INCIDENCE; NEOPLASM RECURRENCE, LOCAL; RISK; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84890214124     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5922     Document Type: Article

References (22)

1. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. New England Journal of Medicine 1988; 318(26):1728-1733.
2. Last JM. A Dictionary of Epidemiology, 2nded. Oxford University Press: New York, 1988.
3. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310:452-454.
4. Connor JT, Imrey PB. Proportions, Inferences, and Comparisons. In Encyclopedia of Biostatistics. John Wiley & Sons, Ltd: 2005. DOI: 10.1002/0470011815.b2a10047.
5. Salah AB, Messaoud NB, Guedri E, Zaatour A, Alaya NB, Bettaieb J, Gharbi A, Hamida NB, Boukthir A, Chlif S, Abdelhamid K, Ahmadi ZE, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishmandeitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, Mccarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. New England Journal of Medicine 2013; 368:524-532.
6. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998; 317:1309-1312.
7. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Annals of Internal Medicine 1997; 126:712-720.
8. Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA, Weinstein RA, Sepkowitz KA, Jernigan JA, Sanogo K, Wong ES. Effect of daily chlorhexidine bathing on hospital-acquired infection. New England Journal of Medicine 2013; 368:533-542.
9. Altman DG, Andersen PK. Calculating the number needed to treat for the trials where the outcome is time to event. BMJ 1999; 319:1492-1495.
10. Koller MD, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical community: irrelevance or ignorance? Statistics in Medicine 2012; 31:1089-1097.
11. Cummings FJ, Gray R, Tormey DC, Davis TE, Volk H, Harris J, Falkson G, Bennett JM. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. Journal of Clinical Oncology 1993; 11:29-35.
12. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. Journal of the American Statistical Association 1999; 94:496-509.
13. Pepe MS. Inference for events with dependent risks in multiple endpoint studies. Journal of the American Statistical Association 1991; 86:770-778.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53:457-481.
15. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, 1980.
16. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data. Statistics in Medicine 1993; 12:737-751.
17. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 1999; 18:695-706.
18. Tsiatis A. A nonidentifiability aspect of the problem of competing risks. Proceedings of the National Academy of Sciences of the United States of America 1975; 72:20-22.
19. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 1988; 16:1141-1154.
20. Breslow NE. Contribution to the discussion of paper by D.R.Cox, regression models and life tables. Journal of the Royal Statistical Society Series B 1972; 34:216-217.
21. Fine JP. Regression modeling of competing crude failure probabilities. Biostatistics 2001; 2:85-97.
22. Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time. Statistics in Medicine 2007; 26:4505-4519.